3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Sarcoma, Ewing
2
Osteosarcoma
2
Neuroblastoma
2
Rhabdoid Tumor
1
Osteosarcoma Recurrent
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Follicular
1
Glioma
1
Glioblastoma
1
Diffuse Intrinsic Pontine Glioma
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Bevacizumab
56
Cetuximab
50
Fluorouracil
45
Leucovorin
39
Oxaliplatin
38
pembrolizumab
31
Specimen Handling
27
Irinotecan
25
Magnetic Resonance Spectroscopy
17
Biopsy
17
Nivolumab
15
HMPL-013
13
Folfox protocol
13
Capecitabine
13
Gemcitabine
12
Cisplatin
12
trifluridine tipiracil drug combination
11
Panitumumab
11
Carboplatin
11
Pemetrexed
9
IFL protocol
9
encorafenib
8
balstilimab
8
Standard of Care
8
Paclitaxel
8
Early Intervention, Educational
8
130-nm albumin-bound paclitaxel
8
fludarabine
7
atezolizumab
7
Educational Status
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Eflornithine
×
90 days
×
Clear all
NCT01349881
2026-04-02
PACES
SWOG Cancer Research Network
Phase 3
Active not recruiting
354 enrolled